Itraconazole vs. trimethoprim–sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis

dc.creatorBorges, Sheila Rocha Conceição
dc.creatorSilva, Gilberto Marcelo Sperandio da
dc.creatorChambela, Mayara da Costa
dc.creatorOliveira, Raquel de Vasconcelos Carvalhães
dc.creatorCosta, Regina Lana Braga
dc.creatorWanke, Bodo
dc.creatorValle, Antonio Carlos Francesconi do
dc.date2015-07-09T13:39:43Z
dc.date2015-07-09T13:39:43Z
dc.date2014
dc.date.accessioned2023-09-26T23:46:42Z
dc.date.available2023-09-26T23:46:42Z
dc.identifierBORGES, Sheila Rocha Conceição et al. Itraconazole vs. trimethoprim–sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis. Medical Mycology, v. 52, n. 3, p. 303-310, 2014.
dc.identifier1369-3786
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/11185
dc.identifier10.1093/mmy/myt012
dc.identifier1460-2709
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8894107
dc.descriptionThe Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation (FIOCRUZ), funded this study.
dc.descriptionParacoccidioidomycosis (PCM) is a systemic mycosis endemic to Latin America. Brazil accounts for approximately 80% of cases, where it represents a major public health issue due to its disabling impact and the number of premature deaths it causes. We present a retrospective cohort study that was conducted in order to better understand factors that relate to cure of the infection in the treatment of 200 patients with PCM. We evaluated the influence of sociodemographic and clinical factors as well as therapeutic regimen (trimethoprim–sulfamethoxazole [TMP–SMX] and itraconazole) on the progress of PCM (cure and noncure). There was a higher incidence of cure (83%) among patients who regularly received treatment for their infections and completed the treatment protocol. Moreover, itraconazole (86.4%) was significantly superior to TMP–SMX (51.3%) in terms of cure rate and had a median treatment period that was significantly shorter (12 months) than that for TMP–SMX (23 months). A Cox proportional hazard regression model showed that use of itraconazole increased the hazard of cure, regardless of sex, age, education, clinical form, completion of treatment, and regularity. Although the results of this study show that itraconazole was the best treatment option for PCM patients, a double-blind, randomized, controlled trial is necessary to confirm this conclusion.
dc.formatapplication/pdf
dc.languageeng
dc.publisherOxford University Press
dc.rightsrestricted access
dc.subjectParacoccidioidomycosis
dc.subjectTrimethoprim-sulfamethoxazole combination
dc.subjectItraconazole
dc.subjectStatistical analysis
dc.subjectParacoccidioidomicose
dc.subjectCombinação trimetoprima-sulfametoxazol
dc.subjectItraconazol
dc.subjectAnálise estatística
dc.titleItraconazole vs. trimethoprim–sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis
dc.typeArticle


Este ítem pertenece a la siguiente institución